Towards Clinical AKT Inhibition in Glioblastoma

Documenti analoghi

• KDM5B predicts temozolomide-resistant subclones in glioblastoma
  di: Vivien Ullrich, et al.
  Pubblicazione: (2024-01-01)
• Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
  di: I-Na Lu, et al.
  Pubblicazione: (2021-06-01)
• Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
  di: Martin Glas, et al.
  Pubblicazione: (2019-12-01)
• Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
  di: Niklas Schäfer, et al.
  Pubblicazione: (2019-03-01)
• Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma
  di: Teresa Schmidt, et al.
  Pubblicazione: (2021-04-01)